Trials / Completed
CompletedNCT04827901
XEN1101 for Major Depressive Disorder
A Proof of Concept Randomized Controlled Trial of XEN1101 for the Treatment of Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- James Murrough · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XEN1101 | two 10 mg capsules |
| DRUG | Placebo | matching placebo |
Timeline
- Start date
- 2021-10-19
- Primary completion
- 2024-10-03
- Completion
- 2024-11-07
- First posted
- 2021-04-01
- Last updated
- 2025-04-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04827901. Inclusion in this directory is not an endorsement.